Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.
You may also be interested in...
Columbia’s Progesterone Faces FDA Skepticism Over Foreign Data At Advisory Committee
The agency rejects the sponsor’s statistical analysis and says there is no statistically significant evidence of efficacy in the U.S. population, and the product seems likely to face a request for another trial from the advisory panel.
Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
Ascend’s 100 reps will detail the progesterone gel to over 14,000 women’s health physicians.
Columbia Expands Prochieve's Reach Beyond Infertility Market With Ascend License Agreement
Ascend’s 100 reps will detail the progesterone gel to over 14,000 women’s health physicians.